1/10/2021 - Press release
Patients with chronic obstructive pulmonary disease (COPD) who also suffer from a blood iron deficiency significantly improve their physical fitness if they receive supplements of this mineral. This is a new approach to the disease, which has been validated by the first studies published in Spain in this field and the largest in the world, to date, involving 66 patients. The work, derived from the FACE-Ferinject Assessment study on improving Exercise Tolerance in patients suffering COPD and iron deficiency, was carried out by doctors and researchers in the Pneumology Department at Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) and has been published in the journals Archivos de Bronconeumología and Biomedicines.
Més informació "Iron supplements improve physical fitness and quality of life in COPD patients"
15/12/2020 - Press release
DNA damage levels and the activity of the polymerase enzyme responsible for cell repair (PARP) increase in lung tumours in patients suffering chronic obstructive pulmonary disease (COPD), but not in people who do not have this pathology. This is reflected in work by researchers from the CIBER of Respiratory Diseases (CIBERES) and doctors and researchers from the Hospital del Mar Pneumology Service and the Hospital del Mar Medical Research Institute research group on muscle wasting and cachexia in chronic respiratory diseases and lung cancer (IMIM-Hospital del Mar), published in the journal Cancers This research is of enormous importance given that treating lung cancer with PARP enzyme inhibitors (already in clinical use for other tumours, such as breast and ovarian cancers) is preferentially indicated for patients with an underlying respiratory disease, while the response in people with no COPD is highly controversial.
Més informació "The presence of COPD, a determining factor in lung cancer treatment"
18/12/2020 - Press release
The journal Neurology has just published the most complete and exhaustive study to date on the survival rate and sequelae of patients who suffer a ruptured brain aneurysm, a disease known as subarachnoid haemorrhage. The work was carried out by doctors at Hospital del Mar (from the Neurology, Neurosurgery, Intensive Medicine, Interventional Neuroradiology, Radiology and Anaesthesia and Resuscitation services) and researchers from the Hospital del Mar Medical Research Institute (IMIM). The results show that the strategy implemented in Catalonia to cover emergency care for this condition produces results comparable to those of the most advanced centres in the world. The data analysed corresponds to 311 patients with aneurysmal subarachnoid haemorrhage treated at Hospital del Mar over the last 12 years. The short-term mortality rate is between 8.7% (one week after treatment, during the hospitalisation period), and 18.4% (after three months). One year after the vascular event, this figure reaches 22.9% and, five years later, 29%. Only 7% of the patients who survived after five years presented disabling sequelae. According to several studies, deaths from this pathology around the world are between 11% and 27.5% in hospital and over 30% after three months.
Més informació "Only 7% of patients treated for a brain aneurysm suffer long-term sequelae"
17/11/2020 - Press release
Nutritional parameters such as body mass index and tests including albumin and total protein levels quantified prior to lung cancer surgery in patients with chronic obstructive pulmonary disease (COPD) predict their 10 year survival, regardless of tumour-related factors and/or chest surgery. This is reflected in the work of researchers from the CIBER of Respiratory Diseases (CIBERES) and doctors and researchers from the Hospital del Mar Pneumology Service and the Hospital del Mar Medical Research Institute research group on muscle wasting and cachexia in chronic respiratory diseases and lung cancer (IMIM-Hospital del Mar), published in the journal of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) Archivos de Bronconeumología. The researchers studied the nutritional status of lung cancer and COPD patients who required surgery and the relationship of this with post-operative survival. To do this, they analysed the nutritional status of 125 patients from Hospital del Mar, 87 of whom had COPD and lung cancer and 38 of whom had cancer but no COPD, before they underwent chest surgery. The patients were monitored for 10 years in order to study their differential survival rates according to the presence or absence of COPD.
15/10/2020 - Press release
They believe that the treatment currently used in many cases, based solely on short-acting bronchodilators like the well-known Ventolin, may increase the risk of severe asthma attacks. This is revealed by a study published in the journal Archivos de Bronconeumología. They advocate the use of inhaled corticoids, which is also the treatment recommended by the international Global Initiative for Asthma (GINA). Asthma is increasingly prevalent and affects 5-10% of the general population. Unfortunately, the decline in associated mortality has slowed in recent years. In the current context, characterised by the COVID-19 epidemic, there is no evidence that suffering asthma implies a more severe form of COVID-19.
24/07/2020 - Press release
One simple call to go over colonoscopy preparation instructions 48 hours before an appointment increases test success by 11.5%. This has been demonstrated in a multi-centre study led by doctors and nurses from the Digestive Tract Service at Hospital del Mar and researchers from the Clinical and Translational Research Group on Colorectal Neoplasia at the Hospital del Mar Medical Research Institute (IMIM). The work, published in the journal Endoscopy, analysed data from 657 patients from 11 Spanish hospitals. This is the first multi-centre study to analyse how an educational approach can improve colon preparation in people at high risk of not achieving this.
21/01/2020 - Press release
Cytomegalovirus infection is a highly prevalent pathology among patients who have undergone a kidney transplant. Studies carried out at the Hospital del Mar and the Hospital del Mar Medical Research Institute indicate that it affects up to 30% of patients in the 6-month period following the operation. That is why finding elements that can act as infection risk markers for this virus is so important. A team of doctors from the hospital and researchers from the IMIM have demonstrated the role that one type of immune system cell, NK (Natural Killer) cells expressing a specific receptor (NKG2C), plays in predicting the risk of developing infection, complementing the existing conventional marker based on T-cell analysis.
28/06/2019 - Press release
The ageing of NK lymphocytes circulating in the blood of patients with HER2-positive breast cancer is a marker that can predict the success or failure of monoclonal antibody therapies, which act on a specific factor in tumour cells. This is the conclusion of a study led by researchers from the Hospital del Mar Medical Research Institute (IMIM) and the Pompeu Fabra University, and doctors from the Hospital del Mar, published in the journal Cancer Immunology Research. The study also involved staff from the Medical Oncology Service at Hospital Clínic in Valencia, the Pathological Anatomy Services at Hospital del Mar, Fundación Jiménez Díaz in Madrid, and the Immunogenetics Service at Puerta de Hierro University Institute, also in Madrid. It involved analysing blood samples from 66 patients, immunogenetic and functional studies of the NK lymphocytes of these patients, as well as analysing tumour biopsies. The ageing of these cells was measured by quantifying the NK lymphocytes in the blood that express the CD57 molecule. The results show that patients with high blood counts at the time of diagnosis are more likely to be resistant to chemotherapy and anti-HER2 antibody treatment.
Més informació "Possible marker of treatment resistance in HER2 breast cancer identified"
04/04/2019 - Press release
Doctors and researchers at Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) have shown, for the first time, that osteoporosis and bone fractures in HIV sufferers is caused by the body's response to the presence of the virus, in the form of inflammatory processes, and not only the antiretroviral treatment, as was previously believed. The study, published in the Journal of Antimicrobial Chemotherapy, used a bone-quality measuring technique designed in the United States in collaboration with staff from Hospital del Mar, together with a protocol developed by the same people, which shows that the risk of fractures is related to the inflammation caused by the chronic infection. This represents a change in how this problem is conceived, as well as how it is approached. The study involved staff from the Infectious Diseases and Internal Medicine services at Hospital del Mar, as well as members of the IMIM's Musculoskeletal Research Group. Dr. Todd T. Brown, from Johns Hopkins University, in the United States, also participated.
Més informació "Paradigm shift in how bone fractures are avoided in HIV patients"
19/11/2018 - Press release
Having certain specific variants of the PATJ gene predisposes to worse recovery from ischemic stroke. 7 out of 10 patients with these variants suffer severe sequelae three months after having a stroke, in other words, they are in a situation of dependence, compared to less than half of patients who do not present these variants. This is data from an international, multicentre study coordinated by researchers at the Hospital del Mar Medical Research Institute (IMIM) and doctors from the Hospital del Mar, published in the journal Circulation Research. This is the most important research carried out so far in the field of genetics and stroke prognosis, and the first published: it uses data from more than 2,000 patients and involves 12 centres from around the world. The study was carried out thanks to the help of the 2010 edition of La Marató de TV3.
Més informació "Gene vital for post-stroke recovery identified for the first time"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
